 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||| frevecitinib (KN-002) / Vectura, Kinaset Therap
Trial completion: Single and Multiple Ascending Dose Study of KN-002 (clinicaltrials.gov) - Aug 7, 2024
P1, N=117, Completed, Sponsor: Kinaset Therapeutics Inc
Active, not recruiting --> Completed
- frevecitinib (KN-002) / Vectura, Kinaset Therap
Late Breaking Abstract - The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD (PS-11; Poster board no. 18) - Jul 16, 2024 - Abstract #ERS2024ERS_5829;
P1
Inhaled KN-002 was well tolerated by subjects with COPD on background therapy. Outcomes support further evaluation to determine the clinical efficacy of KN-002 in subjects with COPD.
- frevecitinib (KN-002) / Vectura, Kinaset Therap
Safety and PK of KN-002 in subjects with moderate to severe asthma using ICS/LABA (A1) - May 31, 2024 - Abstract #ERS2024ERS_3519;
P1
Inhaled KN-002 was well tolerated by subjects with moderate to severe asthma using ICS/LABA. Outcomes support the Phase 2 development in subjects with uncontrolled asthma using medium to high dose ICS/LABA treatment.
- frevecitinib (KN-002) / Vectura, Kinaset Therap
KN-002 reduces fractional exhaled nitric oxide in moderate to severe asthma (Lehar 3) - May 31, 2024 - Abstract #ERS2024ERS_2671;
P1
KN-002 caused clinically relevant FeNO reduction over 10 days independent of baseline FeNO / blood eosinophils. These results support KN-002 development in eosinophilic and non-eosinophilic moderate to severe asthma.
- KN-002 / Vectura, Kinaset Therap
Clinically Relevant Reductions in FeNO Reported After 10-day Treatment With KN-002 in Subjects With Mild Asthma (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5590;
P1
Maximal response was observed at a dose (4 mg BID) administered via a single unit-dose capsule. These outcomes supported the further evaluation of a 4 mg BID regimen in subjects with moderate to severe asthma despite use of concomitant ICS/LABA therapy.
- || frevecitinib (KN-002) / Vectura, Kinaset Therap
Enrollment closed, Trial completion date, Trial primary completion date: Single and Multiple Ascending Dose Study of KN-002 (clinicaltrials.gov) - Jan 5, 2024
P1, N=117, Active, not recruiting, Sponsor: Kinaset Therapeutics Inc
These outcomes supported the further evaluation of a 4 mg BID regimen in subjects with moderate to severe asthma despite use of concomitant ICS/LABA therapy. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Dec 2023
- || frevecitinib (KN-002) / Vectura, Kinaset Therap
Enrollment change, Trial completion date, Trial primary completion date: Single and Multiple Ascending Dose Study of KN-002 (clinicaltrials.gov) - Sep 1, 2022
P1, N=128, Recruiting, Sponsor: Kinaset Therapeutics Inc
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Dec 2023 N=80 --> 128 | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Apr 2023
- | frevecitinib (KN-002) / Vectura, Kinaset Therap
New P1 trial: Single and Multiple Ascending Dose Study of KN-002 (clinicaltrials.gov) - Aug 16, 2021
P1, N=80, Recruiting, Sponsor: Kinaset Therapeutics Inc
- KN-002 / Vectura, Kinaset Therap
[VIRTUAL] The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. () - Jul 29, 2021 - Abstract #ERS2021ERS_2087;
KN-002 is a potent and broad inhibitor of IL-13- and IFNγ+TNFα-induced inflammation implicated in the pathogenesis of Th2-high and Th2-low asthma ex vivo. The data support a potential therapeutic role in severe asthma and COPD.
- ||||||| frevecitinib (KN-002) / Vectura, Kinaset Therap
Trial completion: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma (clinicaltrials.gov) - Mar 10, 2017
P, N=10, Completed, Sponsor: Imperial College London
The data support a potential therapeutic role in severe asthma and COPD. Recruiting --> Completed
- frevecitinib (KN-002) / Vectura, Kinaset Therap
New trial: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma (clinicaltrials.gov) - Apr 15, 2016
P0, N=9, Recruiting, Sponsor: Imperial College London